3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

98.39 +8.39 ( +9.32% ) 4:02 3/30/20 Pricing delayed 20 minutes

Volume 461,621

Recent News

See All
February 28, 2020 Nevro and Stimwave Reach Worldwide Settlement in Patent Infringement Lawsuit: Stimwave Agrees to a Permanent Injunction
- Stimwave To Cease Commercialization of Spinal Cord Stimulation Products Delivering Therapy Between 1,500 Hz and 100,000 Hz -  Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the settlement of its patent infringement lawsuit against Stimwave Technologies, Inc.  Stimwave has agreed to cease commercialization of all high frequency spinal cord stimulation systems worldwide. The lawsuit was filed in the United States District Court for the District of Delaware on February 14, 2019, and asserted, among other things, that Stimwave was infringing Nevro's patents covering inventions relating to Nevro's groundbreaking Senza® system and HF10® therapy.  In July 2019, the District of Delaware issued a preliminary injunction against Stimwave.  Stimwave has now agreed to a permanent injunction under which Stimwave's products will not deliver spinal cord stimulation therapy that...
February 28, 2020 Nevro Files Lawsuit for Patent Infringement Against Nalu Medical in the U.S.
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it has filed a lawsuit for patent infringement against Nalu Medical, Inc.  The lawsuit, filed in the United States District Court for the District of Delaware on February 28, 2020, asserts that Nalu is infringing Nevro's patents covering inventions relating to Nevro's groundbreaking Senza® system and HF10® therapy. "We have long held that intellectual property is the basis for innovation in medical technology given the long development timelines, investment and risk required to bring meaningful advances to market," said Kashif Rashid, General Counsel, Nevro. "We remain fully committed to protecting our intellectual property portfolio so that we may continue our mission to transform patients' lives with HF10 therapy." Documents relating to the lawsuit will be available via registration at the court's website,...
February 25, 2020 Nevro Reports Fourth Quarter and Full Year 2019 Financial Results
Provides Expanded 2020 Guidance
Fourth Quarter 2019 and Recent Highlights
- U.S. Patient Trials Grew 17% and Permanent Implants Grew 20% Over Prior Year
- Senza® Omnia™ SCS System Commercially Launched in U.S.
- Senza-PDN 3-month RCT Data Presented at North American Neuromodulation Society (NANS) 2020 Conference  Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the fourth quarter and full year ended December 31, 2019. Fourth Quarter 2019 Worldwide revenue for the fourth quarter 2019 was $114.4 million, a 6% increase compared to $107.9 million in the prior year period.  U.S. revenue was $97.9 million, a 7% increase compared to $91.6 million in the prior year period.  Year-over-year U.S. trial growth was 17% and permanent implant growth was 20% during the fourth quarter of 2019.  International revenue was $16.5 million, a 1%...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, Senza II, Senza Omnia, HF10, More, Nevro, Nevrocloud, Surpass and the Nevro, HF10, and Frequency Pairing Logos are trademarks of Nevro Corp.